A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Active, not recruiting · Phase 2 · NCT06356571
Conditions: Plasma Cell Myeloma Refractory
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 17
- Sites paid
- 16
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- Sanofi
- Tested
- Isatuximab SC-OBDS (drug), Montelukast (drug), Dexamethasone (drug), Acetaminophen (drug), Diphenhydramine (drug), Methylprednisolone (drug), Carfilzomib (drug)
- Dates
- Started 2025-03-17; completion 2027-07-15
- Results posted
- Not yet
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $1.5M in research payments for this study in 2025 (89 payments).
Products named: Sarclisa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raleigh C. Cutrer, MD Hematology & Oncology · Birmingham, AL
- Syed Ali, M.D. Hospitalist · Hartford, CT
- Chintan C. Gandhi, M.D. Hematology & Oncology · Tamarac, FL
- Isaac Levy, MD Specialist · Hollywood, FL
- Kamal Sharma, D.O. Hematology & Oncology · Lakeland, FL
- David N. Oubre, M.D. Hematology & Oncology · Hammond, LA
- Jeffrey H. Margolis, M.D. Hematology & Oncology · Madison Heights, MI
- Faisal Musa, MD Hematology & Oncology · Dearborn, MI
- David H. Vesole, MD Medical Oncology · Hackensack, NJ
- Carlyn Rose C. Tan, M.D. Medical Oncology · New York, NY
- Edward A. Faber JR., D.O., M.S. Hematology & Oncology · Cincinnati, OH
- Nashat Gabrail, M.D. Specialist · Canton, OH
- David A. Kahn, MD Psychiatry · Providence, RI
- Suzanne R. Fanning, D.O. Hematology & Oncology · Greenville, SC
- George F. Geils JR., M.D. Hematology & Oncology · Charleston, SC
- Saji Eapen, MD Hematology & Oncology · Knoxville, TN
- Shannon E. O'mahar, MD Hematology & Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gabrail Cancer Center Canton $280,394
- Hackensack University Medical Center, NJ $279,605
- Yale University Attn Treasury Services $269,958
- Sloan Kettering Inst for Cancer Research $212,248
- Profound Research Llc $127,806
- Brcr Medical Center Inc $65,807
- University of Cincinnati $46,401
- Clinical Biotechnology Research $35,250
- Helios Cr, Inc $33,627
- $33,490
- Exigent Research Llc $31,810
- Center for Biomedical Research Llc $24,513
- The University of Tennessee $24,200
- Millennium Oncology Research Clinic Inc $22,534
- Empirican Prn Inc Circuit Clinical $21,245
- Prisma Health Greenville Memorial Hospital, SC $20,537
- D H Cancer Research Center Llc $17,810
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.